Liana G. Apostolova
A5033942521- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Advanced Neuroimaging Techniques and Applications
- Bioinformatics and Genomic Networks
- Neurological Disease Mechanisms and Treatments
- Health, Environment, Cognitive Aging
- Genetic Associations and Epidemiology
- Parkinson's Disease Mechanisms and Treatments
- Brain Tumor Detection and Classification
- Folate and B Vitamins Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Advanced MRI Techniques and Applications
- Epigenetics and DNA Methylation
- Cerebrovascular and Carotid Artery Diseases
- Neural dynamics and brain function
- Cholinesterase and Neurodegenerative Diseases
- S100 Proteins and Annexins
- Health Systems, Economic Evaluations, Quality of Life
- Medical Imaging Techniques and Applications
- Memory and Neural Mechanisms
- GDF15 and Related Biomarkers
- EEG and Brain-Computer Interfaces
- Blood Pressure and Hypertension Studies
- Mental Health Research Topics
Indiana University School of Medicine
2016-2025
Indiana University – Purdue University Indianapolis
2016-2025
Alzheimer’s Disease Neuroimaging Initiative
2013-2025
Indiana University
2018-2024
University of California, Los Angeles
2015-2024
Indiana University Bloomington
2020-2024
University of Pennsylvania
2015-2024
University School
2018-2024
University of California, San Francisco
2015-2024
San Francisco VA Medical Center
2015-2024
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. Design, Setting, Participants Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic disease (mild cognitive impairment/mild dementia) low/medium or high tau pathology...
A hallmark of Alzheimer's disease is the accumulation amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form deposited Aβ, being investigated for treatment early disease.
While most patients with mild cognitive impairment (MCI) transition to Alzheimer disease (AD), others develop non-AD dementia, remain in the MCI state, or improve.To test following hypotheses: smaller hippocampal volumes predict conversion of AD, whereas larger stability and/or improvement; and who convert AD have greater atrophy CA1 subfield subiculum.Prospective longitudinal cohort study.University California-Los Angeles Alzheimer's Disease Research Center.We followed up 20 subjects...
Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) promising candidate for treating human AD. The purpose current study generate tolerability preliminary clinical biomarker efficacy data curcumin persons with AD.We performed 24-week randomized, double blind, placebo-controlled...
Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk Alzheimer's dementia, while APOE2 lower it not yet known whether homozygotes have particularly low risk. We generated dementia odds ratios and other findings in more than 5,000 clinically characterized neuropathologically cases controls. APOE2/2 was compared to APOE2/3 3/3, an exceptionally ratio APOE4/4, impact APOE4 gene dose significantly greater confirmed group 24,000 unconfirmed Finding...
Alzheimer disease (AD) is the most common type of dementia worldwide. Hippocampal atrophy and ventricular enlargement have been associated with AD but also normal aging. We analyzed 1.5-T brain magnetic resonance imaging data from 46 cognitively elderly individuals (NC), 33 mild cognitive impairment 43 patients. analyses were conducted 2 novel semiautomated segmentation approaches followed by radial distance mapping technique. Multiple linear regression was used to assess effects age...
Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on appropriate use this new therapy. An Expert Panel was assembled to construct Appropriate Use Recommendations based participant populations, conduct pivotal trials aducanumab, updated Prescribing Information, expert consensus. is an amyloid-targeting monoclonal antibody delivered monthly intravenous infusions. The included patients with early AD (mild...
Alzheimer's disease (AD) is a complex genetic disorder with no effective treatments. More than 20 common markers have been identified, which are associated AD. Recently, several rare variants identified in Amyloid Precursor Protein (APP), Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) and Unc-5 Netrin C (UNC5C) that affect risk for Despite the many successes, architecture of AD remains unsolved. We used Genome-wide Complex Trait Analysis to (1) estimate phenotypic variance...
Genetic loci for Alzheimer's disease (AD) have been identified in whites of European ancestry, but the genetic architecture AD among other populations is less understood.We conducted a transethnic genome-wide association study (GWAS) late-onset Stage 1 sample including Ancestry, African-Americans, Japanese, and Israeli-Arabs assembled by Disease Genetics Consortium. Suggestive results from novel were followed up using summarized International Genomics Project GWAS dataset.Genome-wide...
Aducanumab (Aduhelm) is approved in the United States for treatment of patients with mild cognitive impairment due to Alzheimer's disease or AD dementia. Appropriate Use Recommendations (AURs) have been published and helped guide best practices use aducanumab. As real-world has occurred more information accrued, AURs require refinement. We update better inform appropriate patient selection improve shared decision-making, safety monitoring, risk mitigation treated patients. Based on evolving...
Alzheimer's disease is the most common neurodegenerative disorder in elderly. Amnestic mild cognitive impairment (MCI) a relatively newly defined clinical entity that requires memory decline while activities of daily living remain intact. Most amnestic MCI patients develop disease. Using an innovative surface-based hippocampal analytic technique we analysed structural magnetic resonance data 31 and 34 subjects. We tested hypothesis subjects have greater atrophy CA1, CA2 CA3 subfields...
Measures are needed that identify persons will develop Alzheimer's disease in order to target them for preventative interventions. There is evidence from animal, pathological and imaging studies disruption of white matter occurs the course may be an early event. Prior have suggested late-myelinating regions or connecting limbic structures particularly susceptible degradation. Persons destined by virtue fully penetrant genetic alterations (familial FAD) provide a model which even...
We compared four automated methods for hippocampal segmentation using different machine learning algorithms: 1) hierarchical AdaBoost, 2) support vector machines (SVM) with manual feature selection, 3) SVM selection (Ada-SVM), and 4) a publicly available brain package (FreeSurfer). trained our approaches T1-weighted MRIs from 30 subjects [10 normal elderly, 10 mild cognitive impairment (MCI), Alzheimer's disease (AD)], tested on an independent set of 40 (20 normal, 20 AD). Manually segmented...
Abstract We used a new method we developed for automated hippocampal segmentation, called the auto context model, to analyze brain MRI scans of 400 subjects from Alzheimer's disease neuroimaging initiative. After training classifier on 21 hand‐labeled expert segmentations, created binary maps hippocampus three age‐ and sex‐matched groups: 100 with (AD), 200 mild cognitive impairment (MCI) elderly controls (mean age: 75.84; SD: 6.64). Hippocampal traces were converted parametric surface...